TARA-002 demonstrated a 100% high-grade complete response in BCG-unresponsive patients at 6 months, with a 76% CR in BCG-naïve patients. The agent acts as a broad-spectrum immune potentiator, ...

Social media platforms are major sources of prostate cancer misinformation, affecting patient education and care provider relationships. Misinformation is often spread by unlicensed individuals posing ...

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s ...

Clarius Prostate AI reduces prostate volume measurement time from minutes to seconds, enhancing clinical efficiency. The application integrates with Clarius handheld ultrasound scanners and calculates ...

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP. When communicating her patients, Anna Myers, CNP, places great ...

The RAPID III trial evaluates the FloStent System, a minimally invasive implant for BPH-related LUTS, enrolling 215 patients across the US and Australia. FloStent offers a non-surgical, reversible ...

The Break Wave System offers a noninvasive, anesthesia-free option for kidney stone treatment using low-pressure ultrasound waves. The SOUND trial enrolled 64 patients to assess the system's safety ...

The release of the first overactive bladder (OAB) guidelines is associated with an increase in OAB diagnoses, a decrease in anticholinergic medication use, and a rise in beta-3 agonist use, according ...

The ARID II trial evaluates the Voro Urologic Scaffold for post-prostatectomy stress urinary incontinence, enrolling 266 patients across 30 US sites. The Voro Urologic Scaffold is designed to support ...

A recent study in JCO Oncology Practice found that in the oncology medical literature, women had a 15% lower Altmetric Attention Score (AAS) as first authors, and an 8% lower (AAS) in the last author ...

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer. 177 Lu-PSMA-617 (Pluvicto) was approved by the FDA in March 2022 for ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...